Through the full cooperation of all departments of the company, fluvastatin sodium sustained-release tablet (80mg) was approved by the State Drug Administration on October 26, 2021. Fluvastatin sodium sustained-release tablet (80mg), as a Sino-US co-line product, has received ANDA APPROVAL from the US FDA on April 26, 2021.
    Our company's fluvastatin sodium sustained-release tablet (80mg) is an imitation of the original product to be suitable and developed, with independent composition prescription patent protection.
    Fluvastatin is A hydroxymethylglutaryl-Coenzyme A (HMG-CoA) reductase suppressant for patients with primary hypercholesterolemia and mixed dyslipidemia (FredricksonⅡa and Ⅱb types) that is not fully controlled by diet.     Fluvastatin not only has a good lipid-regulating effect, but also can effectively protect the vascular endothelium and reduce the thickness of carotid intimedia in hypertensive patients. Fluvastatin is cleared by the liver, and only less than 6% of the drug enters the urine. Compared with similar products, long-term use of fluvastatin has little effect on kidney function, and it is a safe and effective first-line lipid regulator for clinical selection.